RxDoctor Payments Data

Christine Hoover, APRN

Family · Anchorage, AKNPI 1942861778

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 79.7% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $5,107, more than ten times the $78 reported in 2021. Among family clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,005in general payments, 2019–2025

Across 32 payments — averaging $187.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$5K
  • Medtronic$254
  • Ascendis Pharma Endocrinology Inc$186
  • Kyowa Kirin, Inc.$132
  • Novo Nordisk$125
  • Lilly USA, LLC$124
  • plus $396 from 6 others

What the payments were for

  • Consulting fees$3,00050%
  • Travel & lodging$1,20320%
  • Food & beverage$1,79430%
  • Education$80%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,005 in reported general payments places this provider in the 95th percentile of 315 family providers in Alaska.

See all family providers in Alaska

Medicare billing

Part B allowed, 2024
$24,773
Medicare patients
94
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide172$177,722
JardianceEmpagliflozin92$37,435
MounjaroTirzepatide15$27,527
Novolog FlexpenInsulin Aspart36$6,631
Methimazole45$547
Hydrocortisone14$486
SynthroidLevothyroxine Sodium40$447
Metformin Hcl ErMetformin Hcl45$299
Metformin Hcl68$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$177,722172 claims
Lilly USA, LLCMounjaro$124$27,52715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 315 family providers in Alaska.

Other family in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →